ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
December 14, 2023 09:26 ET
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens...
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
November 17, 2023 08:00 ET
|
Serina Therapeutics, Inc.
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a...
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
November 06, 2023 07:45 ET
|
Revive Therapeutics Ltd.
Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd....
F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies
July 05, 2023 08:00 ET
|
F-star Therapeutics, Inc.
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, an invoX company (“F-star”), today announced that it has entered into a strategic discovery collaboration and licence agreement with...
Aridis Provides Corporate Update
March 31, 2023 19:00 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on...
AnaBios Boosts Discovery of Safer, More Effective Medicines With License From the University of Louisville
February 14, 2023 09:00 ET
|
AnaBios
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- AnaBios, a preclinical contract research organization that provides ex vivo human platforms to de-risk new drugs, today announced a technology transfer...
Genmab and Synaffix Enter into License Agreement for ADC Technology
January 04, 2022 09:00 ET
|
Genmab A/S
Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for...
XOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets
April 15, 2021 09:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition...